Drugmaker Faces Civil, Criminal Fines over Megace

Bulletin Today | Personal HealthBy Linda A. Johnson and Samantha Henry of The Associated Press NEWARK, N.J. (AP) — A New Jersey-based drugmaker agreed on Tuesday to pay $45 million to resolve charges that it improperly marketed its weight-gain drug to frail seniors particularly vulnerable to its side effects, federal officials said Tuesday. Officials from Woodcliff Lake-based Par Pharmaceutical Cos. pleaded guilty on behalf of the company to a charge of criminal misbranding. Par CEO Paul V. Campanelli admitted the company had improperly marketed …